Attana has received an contract research order from an European Biotech company.

The order is related to optimization of therapeutically antibodies. The order value is around 600 kSEK and is expected to be performed and delivered during Q3 and Q4 2018 and will affect the cash flow and financial result positively during these two quarters.  The contract is based on Attana’s patented cell-based biosensor and will included detailed interaction analysis between the antibodies and specific cells with the goal of selecting and improving the antibodies interaction characteristic in an biologically relevant environment.

Attana’s application specialists will perform experiments where the interactions between a specific target receptor in the cell membrane of the target cells and a number of different antibodies with therapeutic potential will be characterized with respect to interaction kinetics and binding affinity. The results will be used for selecting and optimizing the most suitable antibody molecules for further development.